Nicotinamide Riboside

Phase 3Small molecule

Nicotinamide Riboside is one of 124 small molecule programs targeting Ataxia-telangiectasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ataxia-TelangiectasiaActive, not recruiting

Hematopoietic Cell TransplantationRecruiting

Chemotherapy-Induced Peripheral NeuropathyActive, not recruiting

Arterial StiffnessRecruiting

Heart FailureActive, not recruiting

Idiopathic Pulmonary FibrosisRecruiting

Vascular DiseaseRecruiting

AgingRecruiting

Ataxia-TelangiectasiaPreclinical

Active, not recruiting

Hematopoietic Cell TransplantationPhase 1

Recruiting

Chemotherapy-Induced Peripheral NeuropathyPhase 2

Active, not recruiting

Arterial StiffnessPhase 2

Recruiting

Heart FailurePhase 1

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Recruiting

Vascular DiseasePhase 1

Recruiting

AgingPhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Nicotinamide Riboside

UUniversity of Oklahoma

Phase 3

1 2

Amidate

Pfizer

Preclinical

1 3

Activase

Zemplar

Savaysa

Xifaxan

2 7

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

GLP-1

RRigshospitalet, Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Idiopathic Pulmonary Fibrosis

NCT06567717

Q3 2027

Phase 1Recruiting

Vascular Disease

NCT06280482

Q4 2027

Post-ApprovalRecruiting

Aging

NCT05483465

Phase 2Active, not recruiting

Chemotherapy-Induced Peripheral Neuropathy

NCT04112641

Q3 2031

Phase 3Not yet recruiting

Peripheral Artery Disease (PAD)

NCT07782671

Clinical

Trials by Indication[1]

Nicotinamide3 trials

The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics

Terminated·MMclean Hospital·Phase 4·NCT03151707·11 enrolled

Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)

Completed·UUniversity of Florida·Phase 1·NCT04112043·147 enrolled

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

Completed·JJohns Hopkins University·Phase 2·NCT03912220·45 enrolled

Arterial Stiffness2 trials

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

Recruiting·DDouglas Seals·Phase 2·NCT03821623·118 enrolled

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04040959·118 enrolled

Ataxia-telangiectasia1 trial

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside

Unknown status·TThe University of Queensland·N/A·NCT06324877·10 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Recruiting·—·Phase 2·NCT06567717·60 enrolled

Hospitalized Patients1 trial

Nicotinamide Riboside in Hospitalized Patients

Completed·OOslo University Hospital·Phase 1/2·NCT04110028·57 enrolled

11 more indications

Terminated·—·Phase 2·NCT03642990·5 enrolled

Aging1 trial

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Recruiting·UUniversity of Oklahoma·Phase 4·NCT05483465·214 enrolled

Heart Failure1 trial

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

Active, not recruiting·UUniversity of Washington·Phase 1·NCT04528004·32 enrolled

Peripheral Artery Disease1 trial

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

Completed·NNorthwestern University·Phase 3·NCT03743636·90 enrolled

Peripheral Artery Disease (PAD)1 trial

Nicotinamide Riboside to Improve Functioning in PAD

Not yet recruiting·NNorthwestern University·Phase 3·NCT07782671·250 enrolled

Chemotherapy-induced Peripheral Neuropathy1 trial

Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Active, not recruiting·DDonna Hammond, PhD·Phase 2·NCT04112641·48 enrolled

Hematopoietic Cell Transplantation1 trial

A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Recruiting·CCase Comprehensive Cancer Center·Phase 1·NCT04332341·20 enrolled

Mild Cognitive Impairment1 trial

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia

Completed·MMclean Hospital·Phase 1·NCT04430517·21 enrolled

Unspecified1 trial

NAD Supplementation and Vascular Health in PAD

Completed·UUniversity of Oklahoma·Phase 1/2·NCT06534944·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Nicotinamide Riboside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotinamide Riboside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotinamide Riboside. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oklahoma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Oklahoma

Nicotinamide Riboside

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q3 2031

Trials by Indication[1]

Nicotinamide3 trials

Arterial Stiffness2 trials

Ataxia-telangiectasia1 trial

Idiopathic Pulmonary Fibrosis1 trial

Hospitalized Patients1 trial

Vascular Disease1 trial

COVID-191 trial

Peripheral Neuropathy1 trial

Aging1 trial

Heart Failure1 trial

Peripheral Artery Disease1 trial

Peripheral Artery Disease (PAD)1 trial

Chemotherapy-induced Peripheral Neuropathy1 trial

Hematopoietic Cell Transplantation1 trial

Mild Cognitive Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News